Trial · NCT02124746
Results by group43
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 43
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities | Total | Subjects with ≥ one AE (any grade) | 73 | Participants | |
| Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities | Total | Subjects with ≥ one Grade 3 or higher AE | 62 | Participants | |
| Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities | Total | Subjects with Grade 3 lab toxicity (highest grade) | 36 | Participants | |
| Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities | Total | Subjects with Grade 4 lab toxicity (highest grade) | 16 | Participants | |
| Splenic Response Rate | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | 20 | Participants | ||
| Splenic Response Rate | Cohort 2 (YM387-II-02/GS-US-352-1154) | 19 | Participants | ||
| Splenic Response Rate | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | 6 | Participants | ||
| Splenic Response Rate | Total | 45 | Participants | ||
| Duration of Splenic Response | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | 1704.5 | Inter-Quartile Range 1153.5 to 2682.0 | days | |
| Duration of Splenic Response | Cohort 2 (YM387-II-02/GS-US-352-1154) | 736.0 | Inter-Quartile Range 197.0 to 1070.0 | days | |
| Duration of Splenic Response | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | 447.5 | Inter-Quartile Range 128.0 to 758.0 | days | |
| Duration of Splenic Response | Total | 990.0 | Inter-Quartile Range 226.0 to 1802.0 | days | |
| Transfusion Independence Response Rate | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | 7 | Participants | ||
| Transfusion Independence Response Rate | Cohort 2 (YM387-II-02/GS-US-352-1154) | 5 | Participants | ||
| Transfusion Independence Response Rate | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | 16 | Participants | ||
| Transfusion Independence Response Rate | Total | 28 | Participants | ||
| Duration of Transfusion Independence Response | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | 357.0 | Inter-Quartile Range 117.0 to 1841.0 | days | |
| Duration of Transfusion Independence Response | Cohort 2 (YM387-II-02/GS-US-352-1154) | 114.0 | Inter-Quartile Range 95.0 to 126.0 | days | |
| Duration of Transfusion Independence Response | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | 281.5 | Inter-Quartile Range 110.0 to 633.5 | days | |
| Duration of Transfusion Independence Response | Total | 193.5 | Inter-Quartile Range 110.0 to 701.0 | days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02124746/results